Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study

J. Bousquet; D. P. Caimmi; A. Bedbrook; M. Bewick; P. W. Hellings; P. Devillier; S. Arnavielhe; C. Bachert; K. C. Bergmann; G. W. Canonica; N. H. Chavannes; A. A. Cruz; R. Dahl; P. Demoly; G. De Vries; E. Mathieu-Dupas; A. Finkwagner; J. Fonseca; N. Guldemond; T. Haahtela; B. Hellqvist-Dahl; J. Just; T. Keil; L. Klimek; M. L. Kowalski; M. Kuitunen; P. Kuna; V. Kvedariene; D. Laune; A. M. Pereira; P. Carreiro-Martins; E. Melén; M. Morais-Almeida; J. Mullol; A. Muraro; R. Murray; L. Nogueira-Silva; N. G. Papadopoulos; G. Passalacqua; F. Portejoie; D. Price; D. Ryan; B. Samolinski; A. Sheikh; V. Siroux; O. Spranger; A. Todo Bom; P. V. Tomazic; A. Valero; E. Valovirta; A. Valiulis; O. Vandenplas; S. van der Meulen; M. van Eerd; M. Wickman; T. Zuberbier

doi:10.1111/all.13125

Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study

J. Bousquet^*, D. P. Caimmi, A. Bedbrook, M. Bewick, P. W. Hellings, P. Devillier, S. Arnavielhe, C. Bachert, K. C. Bergmann, G. W. Canonica, N. H. Chavannes, A. A. Cruz, R. Dahl, P. Demoly, G. De Vries, E. Mathieu-Dupas, A. Finkwagner, J. Fonseca, N. Guldemond, T. HaahtelaB. Hellqvist-Dahl, J. Just, T. Keil, L. Klimek, M. L. Kowalski, M. Kuitunen, P. Kuna, V. Kvedariene, D. Laune, A. M. Pereira, P. Carreiro-Martins, E. Melén, M. Morais-Almeida, J. Mullol, A. Muraro, R. Murray, L. Nogueira-Silva, N. G. Papadopoulos, G. Passalacqua, F. Portejoie, D. Price, D. Ryan, B. Samolinski, A. Sheikh, V. Siroux, O. Spranger, A. Todo Bom, P. V. Tomazic, A. Valero, E. Valovirta, A. Valiulis, O. Vandenplas, S. van der Meulen, M. van Eerd, M. Wickman, T. Zuberbier

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

91 Citations (Scopus)

Abstract

Background: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms).

Aims: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions.

Methods: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms.

Results: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction.

Conclusions: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.

Original language	English
Pages (from-to)	857–865
Number of pages	9
Journal	Allergy
Volume	72
Issue number	6
Early online date	21 Feb 2017
DOIs	https://doi.org/10.1111/all.13125
Publication status	Published - 1 Jun 2017

Bibliographical note

Funding
Unrestricted educational grant from Meda (Bad Homburg, Germany) and Structural Development Funds of the European Union (Région Languedoc Roussillon). The App belongs to the Région Occitanie (formerly Languedoc-Roussillon, Midi-Pyrénées, France). MASK is a project of the B3 Action Plan of the European Innovation Partnership on Active and Healthy Ageing (DG Santé and DG CONNECT) and of the ‘Twinning’ (transfer of innovation) of the App in 13 EU Regions (European Innovation Partnership on Active and Healthy Ageing).

Keywords

Allergy Diary
Allergen immunotherapy
EIP on AHA
MASK-rhinitis
Mobile technology

Access to Document

10.1111/all.13125Licence: Unspecified

Cite this

Bousquet, J., Caimmi, D. P., Bedbrook, A., Bewick, M., Hellings, P. W., Devillier, P., Arnavielhe, S., Bachert, C., Bergmann, K. C., Canonica, G. W., Chavannes, N. H., Cruz, A. A., Dahl, R., Demoly, P., De Vries, G., Mathieu-Dupas, E., Finkwagner, A., Fonseca, J., Guldemond, N., ... Zuberbier, T. (2017). Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study. Allergy, 72(6), 857–865. https://doi.org/10.1111/all.13125

Bousquet, J, Caimmi, DP, Bedbrook, A, Bewick, M, Hellings, PW, Devillier, P, Arnavielhe, S, Bachert, C, Bergmann, KC, Canonica, GW, Chavannes, NH, Cruz, AA, Dahl, R, Demoly, P, De Vries, G, Mathieu-Dupas, E, Finkwagner, A, Fonseca, J, Guldemond, N, Haahtela, T, Hellqvist-Dahl, B, Just, J, Keil, T, Klimek, L, Kowalski, ML, Kuitunen, M, Kuna, P, Kvedariene, V, Laune, D, Pereira, AM, Carreiro-Martins, P, Melén, E, Morais-Almeida, M, Mullol, J, Muraro, A, Murray, R, Nogueira-Silva, L, Papadopoulos, NG, Passalacqua, G, Portejoie, F, Price, D, Ryan, D, Samolinski, B, Sheikh, A, Siroux, V, Spranger, O, Todo Bom, A, Tomazic, PV, Valero, A, Valovirta, E, Valiulis, A, Vandenplas, O, van der Meulen, S, van Eerd, M, Wickman, M & Zuberbier, T 2017, 'Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study', Allergy, vol. 72, no. 6, pp. 857–865. https://doi.org/10.1111/all.13125

@article{8baf44185ee9401dbeb688d73ceed7f5,

title = "Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study",

abstract = "Background: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). Aims: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. Methods: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. Results: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. Conclusions: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.",

keywords = "Allergy Diary, Allergen immunotherapy, EIP on AHA, MASK-rhinitis, Mobile technology",

author = "J. Bousquet and Caimmi, {D. P.} and A. Bedbrook and M. Bewick and Hellings, {P. W.} and P. Devillier and S. Arnavielhe and C. Bachert and Bergmann, {K. C.} and Canonica, {G. W.} and Chavannes, {N. H.} and Cruz, {A. A.} and R. Dahl and P. Demoly and {De Vries}, G. and E. Mathieu-Dupas and A. Finkwagner and J. Fonseca and N. Guldemond and T. Haahtela and B. Hellqvist-Dahl and J. Just and T. Keil and L. Klimek and Kowalski, {M. L.} and M. Kuitunen and P. Kuna and V. Kvedariene and D. Laune and Pereira, {A. M.} and P. Carreiro-Martins and E. Mel{\'e}n and M. Morais-Almeida and J. Mullol and A. Muraro and R. Murray and L. Nogueira-Silva and Papadopoulos, {N. G.} and G. Passalacqua and F. Portejoie and D. Price and D. Ryan and B. Samolinski and A. Sheikh and V. Siroux and O. Spranger and {Todo Bom}, A. and Tomazic, {P. V.} and A. Valero and E. Valovirta and A. Valiulis and O. Vandenplas and {van der Meulen}, S. and {van Eerd}, M. and M. Wickman and T. Zuberbier",

note = "Funding Unrestricted educational grant from Meda (Bad Homburg, Germany) and Structural Development Funds of the European Union (R{\'e}gion Languedoc Roussillon). The App belongs to the R{\'e}gion Occitanie (formerly Languedoc-Roussillon, Midi-Pyr{\'e}n{\'e}es, France). MASK is a project of the B3 Action Plan of the European Innovation Partnership on Active and Healthy Ageing (DG Sant{\'e} and DG CONNECT) and of the {\textquoteleft}Twinning{\textquoteright} (transfer of innovation) of the App in 13 EU Regions (European Innovation Partnership on Active and Healthy Ageing).",

year = "2017",

month = jun,

day = "1",

doi = "10.1111/all.13125",

language = "English",

volume = "72",

pages = "857–865",

journal = "Allergy",

issn = "0105-4538",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "6",

}

TY - JOUR

T1 - Pilot study of mobile phone technology in allergic rhinitis in European countries

T2 - The MASK-rhinitis study

AU - Bousquet, J.

AU - Caimmi, D. P.

AU - Bedbrook, A.

AU - Bewick, M.

AU - Hellings, P. W.

AU - Devillier, P.

AU - Arnavielhe, S.

AU - Bachert, C.

AU - Bergmann, K. C.

AU - Canonica, G. W.

AU - Chavannes, N. H.

AU - Cruz, A. A.

AU - Dahl, R.

AU - Demoly, P.

AU - De Vries, G.

AU - Mathieu-Dupas, E.

AU - Finkwagner, A.

AU - Fonseca, J.

AU - Guldemond, N.

AU - Haahtela, T.

AU - Hellqvist-Dahl, B.

AU - Just, J.

AU - Keil, T.

AU - Klimek, L.

AU - Kowalski, M. L.

AU - Kuitunen, M.

AU - Kuna, P.

AU - Kvedariene, V.

AU - Laune, D.

AU - Pereira, A. M.

AU - Carreiro-Martins, P.

AU - Melén, E.

AU - Morais-Almeida, M.

AU - Mullol, J.

AU - Muraro, A.

AU - Murray, R.

AU - Nogueira-Silva, L.

AU - Papadopoulos, N. G.

AU - Passalacqua, G.

AU - Portejoie, F.

AU - Price, D.

AU - Ryan, D.

AU - Samolinski, B.

AU - Sheikh, A.

AU - Siroux, V.

AU - Spranger, O.

AU - Todo Bom, A.

AU - Tomazic, P. V.

AU - Valero, A.

AU - Valovirta, E.

AU - Valiulis, A.

AU - Vandenplas, O.

AU - van der Meulen, S.

AU - van Eerd, M.

AU - Wickman, M.

AU - Zuberbier, T.

N1 - Funding Unrestricted educational grant from Meda (Bad Homburg, Germany) and Structural Development Funds of the European Union (Région Languedoc Roussillon). The App belongs to the Région Occitanie (formerly Languedoc-Roussillon, Midi-Pyrénées, France). MASK is a project of the B3 Action Plan of the European Innovation Partnership on Active and Healthy Ageing (DG Santé and DG CONNECT) and of the ‘Twinning’ (transfer of innovation) of the App in 13 EU Regions (European Innovation Partnership on Active and Healthy Ageing).

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). Aims: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. Methods: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. Results: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. Conclusions: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.

AB - Background: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). Aims: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. Methods: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. Results: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. Conclusions: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.

KW - Allergy Diary

KW - Allergen immunotherapy

KW - EIP on AHA

KW - MASK-rhinitis

KW - Mobile technology

UR - http://www.scopus.com/inward/record.url?scp=85013460536&partnerID=8YFLogxK

U2 - 10.1111/all.13125

DO - 10.1111/all.13125

M3 - Article

AN - SCOPUS:85013460536

SN - 0105-4538

VL - 72

SP - 857

EP - 865

JO - Allergy

JF - Allergy

IS - 6

ER -

Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this